Abomasal hamartoma in a La Mancha wether

Smith, Joe S.; Klostermann, Cassandra A.; Harm, Tyler; Breuer, Ryan; Kovalik, David A; Bornkamp, Jennifer; Yaeger, Michael J.

doi:10.1136/vetreccr-2017-000515

Cited by 9 publications

(10 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although some cases of post pantoprazole administration anaphylaxis (22,23) and edema (24,25) have been reported in humans, these clinical signs were not observed in our population. While the aim of this study was not to evaluate the clinical safety of pantoprazole in calves, the lack of observed adverse effects correlate with previously reported pantoprazole use in ruminants for case management of cattle (4,26), camels (27), sheep (15,28), yaks (29), and goats (30,31). Adverse effects of pantoprazole administration described people include hyponatremia (32), hypomagnesemia (33), as well as nephritis and hepatotoxicity (34).…”

Section: Discussionsupporting

confidence: 52%

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

et al. 2020

View full text Add to dashboard Cite

Background: Neonatal calves are at risk of developing abomasal ulceration, but there is a lack of pharmacokinetic data for potential anti-ulcerative therapies, such as pantoprazole, in ruminant species.Objective: The study objectives were to estimate plasma pharmacokinetic parameters for pantoprazole in neonatal dairy calves after intravenous (IV) administration. A secondary objective was to quantify the concentrations of pantoprazole in edible tissues after IV dosing.Methods: Pantoprazole was administered to 9 neonatal Holstein calves at a dose of 1 mg/kg IV. Plasma samples were collected over 24 h and analyzed via HPLC-MS for determining pantoprazole concentrations. Pharmacokinetic parameters were derived via non-compartmental analysis. Tissue samples were collected at 1, 3, and 5 days after administration and analyzed via HPLC-MS.Results: Following IV administration, plasma clearance, elimination half-life, and volume of distribution of pantoprazole were estimated at 4.46 mL/kg/min, 2.81 h, and 0.301 L/kg, respectively. The global extraction ratio was estimated at 0.053 ± 0.015. No pantoprazole was detected in the edible tissues 1, 3, or 5 days after administration. A metabolite, pantoprazole sulfone was detected in all the edible tissues 1 and 3 days after administration.Conclusion: The reported plasma clearance for pantoprazole is less than that reported for alpacas but higher than reported in foals. The elimination half-life in calves appears to be longer than observed in foals and alpacas. While pantoprazole sulfone was detected in the tissues after IV administration, further research is needed as to the metabolism and potential tissue accumulation of other pantoprazole metabolites in calves. Future pharmacodynamic studies are necessary to determine the efficacy of pantoprazole on abomasal acid suppression in calves.

show abstract

Section: Discussionsupporting

confidence: 52%

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, that study did not evaluate safety with respect to adverse findings of pantoprazole administration in humans. Case reports involving ruminant species demonstrate use of pantoprazole in goats (3,18), a sheep (19), a beef bull (6), a camel (4), and a yak (5) with no reported complications from administration. Our study provides clinically relevant data to guide veterinary practitioners for the use of pantoprazole in hospitalized ruminants.…”

Section: Discussionmentioning

confidence: 99%

“…In alpacas (2), pantoprazole has been shown to increase third-compartment pH when given at a dose of 1 mg/kg intravenously or 2 mg/kg subcutaneously with high bioavailability when administered subcutaneously. Currently, no pharmacokinetic, pharmacodynamic, or safety studies for pantoprazole exist for cattle, sheep, or goats, although case reports of the use of pantoprazole in individual ruminant animals without observed adverse effects or toxicities do exist (3)(4)(5)(6).…”

Section: Introductionmentioning

confidence: 99%

A Retrospective Clinical Investigation of the Safety and Adverse Effects of Pantoprazole in Hospitalized Ruminants

2020

View full text Add to dashboard Cite

Clinical safety data for the use of gastroprotectants in hospitalized ruminants is lacking. In human patients, multiple adverse effects are possible from the use of pantoprazole including hematologic and electrolyte abnormalities as well as anaphylaxis and edema. The medical records of all hospitalized cattle, goats, and sheep administered pantoprazole over an ∼5-year period were retrospectively analyzed for adverse effects. Seventy-nine eligible patients were observed. Hypomagnesemia was observed after pantoprazole administration in 10 cattle; however, no significant changes were noted when compared to baseline before pantoprazole administration. Significant changes were noted in serum indicators of hepatic and renal function; however, these represented downward trends that were most likely clinically insignificant. Anaphylaxis after pantoprazole administration was not observed; however, seven cattle displayed edema after pantoprazole administration. Veterinary clinicians should be aware of the potential for hypomagnesemia in hospitalized ruminants being administered pantoprazole and monitor patients accordingly. While these preliminary retrospective results indicate that pantoprazole may be a safe adjunctive therapy in hospitalized ruminants, additional studies are necessary to further determine the safety and toxicity of pantoprazole in ruminants.

show abstract

“…In alpacas [16], pantoprazole has been shown to increase third compartment pH when given at a dose of 1 mg/kg intravenously or 2 mg/kg subcutaneously. Among other ruminant species there are cases reporting the use of pantoprazole in a goat and a yak [6, 17]. Reported complications associated with pantoprazole in people include hyponatremia in hospitalized patients as well as neutropenia and thrombocytopenia with long-term use [18, 19].…”

Section: Discussionmentioning

confidence: 99%

Medical Management of Hemorrhagic Bowel Syndrome in a Beef Bull

Smith

Zhou

Merkatoris

et al. 2019

Case Reports in Veterinary Medicine

View full text Add to dashboard Cite

A two and a half-year old Simmental bull was presented to Iowa State University's Food Animal and Camelid Hospital for anorexia and lethargy of several days. Clostridium perfringens type A was identified via fecal culture and toxin genotyping. Hemorrhagic bowel syndrome (HBS) was diagnosed based on microbiological results along with abdominal ultrasonography, complete blood count, and serum biochemistry. Aggressive multi-modal therapy was employed including intravenously administered fluid therapy, potassium penicillin, lidocaine, flunixin, and pantoprazole among other supportive care. The bull was discharged after 15 days of hospitalization and recovered uneventfully to full function by the next breeding season. Currently all case reports with regard to HBS in beef cattle describe mortality. While the dairy cattle literature demonstrates that HBS has a high mortality rate, and suggests that surgical intervention has a higher prognosis when compared to medical therapy in dairy cattle. Our case would provide support to aggressive medical treatment for HBS in beef cattle.

show abstract

Abomasal hamartoma in a La Mancha wether

Cited by 9 publications

References 11 publications

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

Pharmacokinetics and Tissue Levels of Pantoprazole in Neonatal Calves After Intravenous Administration

A Retrospective Clinical Investigation of the Safety and Adverse Effects of Pantoprazole in Hospitalized Ruminants

Medical Management of Hemorrhagic Bowel Syndrome in a Beef Bull

Contact Info

Product

Resources

About